Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A. Konstantinopoulos, Alexandre André Balieiro Anastácio da Costa, D. Gulhan, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 187
Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 120
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1400-1411
Open Access | Times Cited: 47
Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy
Jay Ramanlal Anand, Lilly Chiou, Carly A. Sciandra, et al.
NAR Cancer (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 44
Targeting ATR in patients with cancer
Natalie Ngoi, Patrick G. Pilié, Daniel J. McGrail, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 278-293
Closed Access | Times Cited: 21
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 19
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Vikas Garg, Amit M. Oza
Drugs (2023) Vol. 83, Iss. 15, pp. 1365-1385
Open Access | Times Cited: 25
Unprocessed genomic uracil as a source of DNA replication stress in cancer cells
Sneha Saxena, Christopher S. Nabel, Turner W. Seay, et al.
Molecular Cell (2024) Vol. 84, Iss. 11, pp. 2036-2052.e7
Open Access | Times Cited: 14
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Agnieszka K. Witkiewicz, Vishnu Kumarasamy, Ioannis Sanidas, et al.
Trends in cancer (2022) Vol. 8, Iss. 9, pp. 711-725
Open Access | Times Cited: 30
Replication Stress Defines Distinct Molecular Subtypes Across Cancers
Nobuyuki Takahashi, Se Hyun Kim, Christopher W. Schultz, et al.
Cancer Research Communications (2022) Vol. 2, Iss. 6, pp. 503-517
Open Access | Times Cited: 29
NSAID–Au(I) Complexes Induce ROS-Driven DAMPs and Interpose Inflammation to Stimulate the Immune Response against Ovarian Cancer
Zhongren Xu, Qiuyue Lu, Min Shan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 7813-7833
Closed Access | Times Cited: 21
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Ana Veneziani, Clare L. Scott, Matthew J. Wakefield, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 16
The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer
Alaina C. Larson, Kenadie R. Doty, Joyce C. Solheim
Cancer Medicine (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 6
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer
Nitasha Gupta, Tzu‐Ting Huang, Jayakumar R. Nair, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 701
Open Access | Times Cited: 15
IGF-1R targeting in cancer – does sub-cellular localization matter?
Upendra Kumar Soni, Liam Jenny, Rashmi S. Hegde
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 15
DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities
María Ovejero-Sánchez, Rogelio González‐Sarmiento, Ana B. Herrero
Cancers (2023) Vol. 15, Iss. 2, pp. 448-448
Open Access | Times Cited: 13
The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities
Xingyuan Zhang, Sayali Joseph, Di Wu, et al.
NAR Cancer (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 5
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 5
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance
Sara Polajžer, Katarina Černe
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2545-2545
Open Access
Overcoming PARP inhibitor resistance in ovarian cancer
Pamela Soberanis Pina, Stéphanie Lheureux
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 3, pp. 364-376
Closed Access | Times Cited: 11
Targeting the DNA damage response in cancer
Guffanti Federica, Chiappa Michela, Giovanna Damia
MedComm (2024) Vol. 5, Iss. 11
Open Access | Times Cited: 4
The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling
Lilly Chiou, Deepika Jayaprakash, Gaith N. Droby, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Aberrant enterocyte progenitor clustering as an early life biomarker of Drosophila aging
Constantina Neophytou, Savvas Teloni, Maria Koumouri, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 111967-111967
Open Access
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
Yuzhen Zhou, Judit Börcsök, Elio Adib, et al.
Science Advances (2023) Vol. 9, Iss. 47
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top